KANONA, INC.

Medtech · Private

Predictive biomarker test for preeclampsia risk stratification in pregnancy using maternal serum biomarkers and clinical data

Grants
$306K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Epigenetic phenotyping from liquid biopsy for preeclampsia risk classification during the first trimester$306,223
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
647CBEZ, LLC——
648INTAILOR BARIATRICS, LLC——
649HYPERSOUND MEDICAL, INC.——
650KANONA, INC.——
651RIGHTAIR, LLC——
652INDEE, INC——
653ATMAN THERAPEUTICS CO.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.